Form 4: Director Alpna Seth Sells Keros Therapeutics Shares

Director Alpna Seth sold 2,625 shares of Keros Therapeutics, Inc. common stock on June 4, 2026, pursuant to a Rule 10b5-1 trading plan.

Summary

• Director Alpna Seth disposed of 2,625 shares of Keros Therapeutics (KROS) common stock.
• The shares were sold at a weighted average price of $10.72 per share.
• The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on December 9, 2025.
• Following the transaction, the reporting person retains beneficial ownership of 9,767 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 mechanism, which is a standard and non-discretionary financial activity.

Positives

• The sale was conducted via a pre-planned Rule 10b5-1 trading plan, which typically indicates the sale is for personal financial planning rather than a reaction to non-public information.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on current valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that director sales executed under Rule 10b5-1 plans are standard corporate governance practices in the biotechnology sector, allowing insiders to diversify holdings without triggering concerns regarding material non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity compensation and personal liquidity.
• The scale of the sale (2,625 shares) is relatively minor compared to typical institutional holdings in mid-cap biotech firms.

Stakeholder Impact

• Minimal impact expected on shareholders as the transaction was pre-planned and represents a small portion of the director's holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Keros Therapeutics, KROS, Insider Trading, Form 4, Alpna Seth, Biotech